Point-Of-Care Biosensors Market By Technology (Electrochemical Biosensors, Optical Biosensors, Piezoelectric Biosensors), By Product Type (Handheld Biosensors, Wearable Biosensors, Implantable Biosensors), By Application (Glucose Monitoring, Infectious Disease Detection, Cardiovascular Monitoring, Drug Abuse Detection, Cancer Biomarker Detection, Pregnancy & Fertility Testing), By End-User (Hospitals & Clinics, Home Care Settings, Diagnostic Laboratories, Research Institutes); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Point-Of-Care Biosensors Market was valued at USD 26.4 Billion in 2024-e and will surpass USD 45.0 Billion by 2030; growing at a CAGR of 9.3% during 2025 - 2030.

The Point-of-Care (PoC) biosensors market is expanding rapidly, driven by the increasing demand for real-time, rapid diagnostics and the growing adoption of portable and wearable biosensors. Advancements in biosensor technology, miniaturization, and integration with digital health solutions are revolutionizing the healthcare industry, allowing for immediate disease detection and continuous patient monitoring. The market is further propelled by the rising prevalence of chronic diseases, increasing preference for home-based healthcare, and the demand for cost-effective diagnostic solutions.

Electrochemical Biosensors Segment Is Largest Due to High Sensitivity and Cost-Effectiveness

Electrochemical biosensors dominate the market owing to their high sensitivity, fast response time, and cost-effectiveness. These biosensors are widely used in glucose monitoring, infectious disease detection, and cardiovascular diagnostics. Their ability to provide accurate and real-time results with minimal sample volume makes them the preferred choice in point-of-care testing. Additionally, technological advancements, such as enzyme-based and nanomaterial-integrated electrochemical biosensors, are enhancing their performance and expanding their applications in decentralized healthcare settings.

Wearable Biosensors Segment Is Fastest Growing Due to Rising Adoption of Continuous Monitoring

The wearable biosensors segment is witnessing the fastest growth, driven by the increasing demand for continuous health monitoring and the integration of biosensors with smart devices. These biosensors are extensively used for glucose monitoring, cardiac health tracking, and remote patient management. The rising popularity of fitness and wellness devices, coupled with advancements in non-invasive biosensing technology, is further fueling market expansion. Companies are investing in AI-driven biosensor platforms and cloud-based data analysis, enhancing the potential of wearable biosensors in preventive healthcare.

Glucose Monitoring Segment Is Largest Due to High Prevalence of Diabetes

Glucose monitoring represents the largest application segment, primarily due to the rising global incidence of diabetes and the growing adoption of continuous glucose monitoring (CGM) devices. Point-of-care glucose biosensors enable real-time tracking of blood sugar levels, improving diabetes management and reducing complications. The increasing availability of compact, non-invasive glucose monitors and integration with smartphone apps is further driving market growth. With the ongoing development of pain-free and implantable glucose monitoring solutions, this segment is expected to maintain its dominance.

Cancer Biomarker Detection Segment Is Fastest Growing Due to Increasing Focus on Early Diagnosis

Cancer biomarker detection is emerging as the fastest-growing application, supported by advancements in biosensor technology and the rising demand for early cancer detection. PoC biosensors enable rapid identification of specific cancer markers, facilitating timely intervention and improving patient outcomes. The development of multiplex biosensors capable of detecting multiple biomarkers in a single test is revolutionizing cancer diagnostics. With growing investments in personalized medicine and liquid biopsy-based biosensing, this segment is expected to expand significantly.

Home Care Settings Segment Is Fastest Growing Due to Shift Towards Decentralized Healthcare

The home care settings segment is witnessing rapid growth, fueled by the increasing preference for self-monitoring and home-based diagnostics. The rising geriatric population, the demand for cost-effective healthcare solutions, and advancements in telemedicine have accelerated the adoption of PoC biosensors in home care. Devices such as wearable glucose monitors, portable cardiovascular biosensors, and at-home infectious disease tests are gaining traction. The COVID-19 pandemic further highlighted the need for remote diagnostics, boosting market adoption.

North America Is Largest Market Due to Advanced Healthcare Infrastructure and High Adoption of PoC Devices

North America dominates the PoC biosensors market, driven by a well-established healthcare system, high adoption of advanced diagnostic technologies, and significant investments in R&D. The region has a strong presence of key market players, robust regulatory support, and widespread availability of reimbursement policies for PoC diagnostic devices. The growing trend of personalized medicine, along with increasing consumer awareness regarding self-monitoring solutions, further strengthens North America's market position.

 Point-Of-Care Biosensors Market  Size

Leading Companies and Competitive Landscape

The market is highly competitive, with leading companies such as Abbott Laboratories, Roche Diagnostics, Medtronic, Dexcom, Siemens Healthineers, and Bio-Rad Laboratories driving innovation. These players are focusing on strategic collaborations, product launches, and advancements in biosensor miniaturization to strengthen their market presence. The integration of biosensors with AI and IoT is reshaping the competitive landscape, enabling real-time analytics and remote patient management. With continuous technological advancements, the market is poised for further expansion, fostering the development of next-generation PoC biosensors.

List of Leading Companies:

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Medtronic plc
  • Nova Biomedical
  • LifeScan, Inc.
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • Dexcom, Inc.
  • EKF Diagnostics Holdings plc
  • Sysmex Corporation
  • Acon Laboratories, Inc.
  • PTS Diagnostics
  • Biomerica, Inc.
  • OrSense Ltd.

Recent Developments:

  • Abbott Laboratories introduced a next-generation wearable glucose biosensor in February 2025 to enhance real-time monitoring.
  • Siemens Healthineers AG launched a rapid diagnostic test for infectious diseases in January 2025 for improved point-of-care testing.
  • Dexcom, Inc. expanded its product portfolio in December 2024 with a new continuous glucose monitoring (CGM) device.
  • Quidel Corporation received regulatory approval in November 2024 for a portable biosensor to detect respiratory infections.
  • Medtronic plc partnered with a digital health company in October 2024 to develop AI-powered biosensing solutions.

Report Scope:

Report Features

Description

Market Size (2024-e)

USD 26.4 Billion

Forecasted Value (2030)

USD 45.0 Billion

CAGR (2025 – 2030)

9.3%

Base Year for Estimation

2024-e

Historic Year

2023

Forecast Period

2025 – 2030

Report Coverage

Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments

Segments Covered

Point-Of-Care Biosensors Market By Technology (Electrochemical Biosensors, Optical Biosensors, Piezoelectric Biosensors), By Product Type (Handheld Biosensors, Wearable Biosensors, Implantable Biosensors), By Application (Glucose Monitoring, Infectious Disease Detection, Cardiovascular Monitoring, Drug Abuse Detection, Cancer Biomarker Detection, Pregnancy & Fertility Testing), By End-User (Hospitals & Clinics, Home Care Settings, Diagnostic Laboratories, Research Institutes)

Regional Analysis

North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa)

Major Companies

Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Medtronic plc, Nova Biomedical, LifeScan, Inc., Bio-Rad Laboratories, Inc., Dexcom, Inc., EKF Diagnostics Holdings plc, Sysmex Corporation, Acon Laboratories, Inc., PTS Diagnostics, OrSense Ltd.

Customization Scope

Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements

Frequently Asked Questions

The Point-Of-Care Biosensors Market was valued at USD 26.4 Billion in 2024-e and is expected to grow at a CAGR of 9.3% of over from 2025 to 2030.

Point-of-care biosensors are portable diagnostic devices that provide real-time analysis of biological samples, enabling rapid decision-making.

They are widely used for glucose monitoring, infectious disease detection, cardiovascular assessment, and drug testing.

Wearable biosensors offer continuous health monitoring, real-time data tracking, and improved patient compliance.

Abbott Laboratories, Roche, and Siemens Healthineers are among the leading players in this market.

1. Introduction

   1.1. Market Definition

   1.2. Scope of the Study

   1.3. Research Assumptions

   1.4. Study Limitations

2. Research Methodology

   2.1. Research Approach

      2.1.1. Top-Down Method

      2.1.2. Bottom-Up Method

      2.1.3. Factor Impact Analysis

  2.2. Insights & Data Collection Process

      2.2.1. Secondary Research

      2.2.2. Primary Research

   2.3. Data Mining Process

      2.3.1. Data Analysis

      2.3.2. Data Validation and Revalidation

      2.3.3. Data Triangulation

3. Executive Summary

   3.1. Major Markets & Segments

   3.2. Highest Growing Regions and Respective Countries

   3.3. Impact of Growth Drivers & Inhibitors

   3.4. Regulatory Overview by Country

4. Point-Of-Care Biosensors Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030)

   4.1. Electrochemical Biosensors

   4.2. Optical Biosensors

   4.3. Piezoelectric Biosensors

   4.4. Others

5. Point-Of-Care Biosensors Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030)

   5.1. Handheld Biosensors

   5.2. Wearable Biosensors

   5.3. Implantable Biosensors

   5.4. Others

6. Point-Of-Care Biosensors Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030)

   6.1. Glucose Monitoring

   6.2. Infectious Disease Detection

   6.3. Cardiovascular Monitoring

   6.4. Drug Abuse Detection

   6.5. Cancer Biomarker Detection

   6.6. Pregnancy & Fertility Testing

   6.7. Others

7. Point-Of-Care Biosensors Market, by End-User (Market Size & Forecast: USD Million, 2023 – 2030)

   7.1. Hospitals & Clinics

   7.2. Home Care Settings

   7.3. Diagnostic Laboratories

   7.4. Research Institutes

   7.5. Others

8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030)

   8.1. Regional Overview

   8.2. North America

      8.2.1. Regional Trends & Growth Drivers

      8.2.2. Barriers & Challenges

      8.2.3. Opportunities

      8.2.4. Factor Impact Analysis

      8.2.5. Technology Trends

      8.2.6. North America Point-Of-Care Biosensors Market, by Technology

      8.2.7. North America Point-Of-Care Biosensors Market, by Product Type

      8.2.8. North America Point-Of-Care Biosensors Market, by Application

      8.2.9. North America Point-Of-Care Biosensors Market, by End-User

      8.2.10. By Country

         8.2.10.1. US

               8.2.10.1.1. US Point-Of-Care Biosensors Market, by Technology

               8.2.10.1.2. US Point-Of-Care Biosensors Market, by Product Type

               8.2.10.1.3. US Point-Of-Care Biosensors Market, by Application

               8.2.10.1.4. US Point-Of-Care Biosensors Market, by End-User

         8.2.10.2. Canada

         8.2.10.3. Mexico

    *Similar segmentation will be provided for each region and country

   8.3. Europe

   8.4. Asia-Pacific

   8.5. Latin America

   8.6. Middle East & Africa

9. Competitive Landscape

   9.1. Overview of the Key Players

   9.2. Competitive Ecosystem

      9.2.1. Level of Fragmentation

      9.2.2. Market Consolidation

      9.2.3. Product Innovation

   9.3. Company Share Analysis

   9.4. Company Benchmarking Matrix

      9.4.1. Strategic Overview

      9.4.2. Product Innovations

   9.5. Start-up Ecosystem

   9.6. Strategic Competitive Insights/ Customer Imperatives

   9.7. ESG Matrix/ Sustainability Matrix

   9.8. Manufacturing Network

      9.8.1. Locations

      9.8.2. Supply Chain and Logistics

      9.8.3. Product Flexibility/Customization

      9.8.4. Digital Transformation and Connectivity

      9.8.5. Environmental and Regulatory Compliance

   9.9. Technology Readiness Level Matrix

   9.10. Technology Maturity Curve

   9.11. Buying Criteria

10. Company Profiles

   10.1. Abbott Laboratories

      10.1.1. Company Overview

      10.1.2. Company Financials

      10.1.3. Product/Service Portfolio

      10.1.4. Recent Developments

      10.1.5. IMR Analysis

    *Similar information will be provided for other companies 

   10.2. F. Hoffmann-La Roche Ltd.

   10.3. Siemens Healthineers AG

   10.4. Medtronic plc

   10.5. Nova Biomedical

   10.6. LifeScan, Inc.

   10.7. Quidel Corporation

   10.8. Bio-Rad Laboratories, Inc.

   10.9. Dexcom, Inc.

   10.10. EKF Diagnostics Holdings plc

   10.11. Sysmex Corporation

   10.12. Acon Laboratories, Inc.

   10.13. PTS Diagnostics

   10.14. Biomerica, Inc.

   10.15. OrSense Ltd.

11. Appendix

 

A comprehensive market research approach was employed to gather and analyze data on The Point-Of-Care Biosensors Market In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on Point-Of-Care Biosensors Market The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.

Research Approach -

Secondary Research

Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.

Primary Research

Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:

  • Validating findings and assumptions derived from secondary research
  • Gathering qualitative and quantitative data on market trends, drivers, and challenges
  • Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
  • Assessing the supply-side landscape, including technological advancements and recent developments

Market Size Assessment

A combination of top-down and bottom-up approaches was utilized to analyze the overall size of Point-Of-Care Biosensors Market These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:

  1. Identification of key industry players and relevant revenues through extensive secondary research
  2. Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
  3. Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources

Bottom Up and Top Down -

Data Triangulation

To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.

Please state your requirements.

  • United States+1
  • United Kingdom+44
  • Albania (Shqipëri)+355
  • Algeria (‫الجزائر‬‎)+213
  • American Samoa+1
  • Andorra+376
  • Angola+244
  • Anguilla+1
  • Antigua and Barbuda+1
  • Argentina+54
  • Armenia (Հայաստան)+374
  • Aruba+297
  • Australia+61
  • Austria (Österreich)+43
  • Azerbaijan (Azərbaycan)+994
  • Bahamas+1
  • Bahrain (‫البحرين‬‎)+973
  • Barbados+1
  • Belarus (Беларусь)+375
  • Belgium (België)+32
  • Belize+501
  • Benin (Bénin)+229
  • Bermuda+1
  • Bhutan (འབྲུག)+975
  • Bolivia+591
  • Bosnia and Herzegovina (Босна и Херцеговина)+387
  • Botswana+267
  • Brazil (Brasil)+55
  • British Indian Ocean Territory+246
  • British Virgin Islands+1
  • Brunei+673
  • Bulgaria (България)+359
  • Burkina Faso+226
  • Burundi (Uburundi)+257
  • Cambodia (កម្ពុជា)+855
  • Cameroon (Cameroun)+237
  • Canada+1
  • Cape Verde (Kabu Verdi)+238
  • Caribbean Netherlands+599
  • Cayman Islands+1
  • Central African Republic (République centrafricaine)+236
  • Chad (Tchad)+235
  • Chile+56
  • China (中国)+86
  • Christmas Island+61
  • Cocos (Keeling) Islands+61
  • Colombia+57
  • Comoros (‫جزر القمر‬‎)+269
  • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
  • Congo (Republic) (Congo-Brazzaville)+242
  • Cook Islands+682
  • Costa Rica+506
  • Côte d’Ivoire+225
  • Croatia (Hrvatska)+385
  • Cuba+53
  • Curaçao+599
  • Cyprus (Κύπρος)+357
  • Czech Republic (Česká republika)+420
  • Denmark (Danmark)+45
  • Djibouti+253
  • Dominica+1
  • Dominican Republic (República Dominicana)+1
  • Ecuador+593
  • Egypt (‫مصر‬‎)+20
  • El Salvador+503
  • Equatorial Guinea (Guinea Ecuatorial)+240
  • Eritrea+291
  • Estonia (Eesti)+372
  • Ethiopia+251
  • Falkland Islands (Islas Malvinas)+500
  • Faroe Islands (Føroyar)+298
  • Fiji+679
  • Finland (Suomi)+358
  • France+33
  • French Guiana (Guyane française)+594
  • French Polynesia (Polynésie française)+689
  • Gabon+241
  • Gambia+220
  • Georgia (საქართველო)+995
  • Germany (Deutschland)+49
  • Ghana (Gaana)+233
  • Gibraltar+350
  • Greece (Ελλάδα)+30
  • Greenland (Kalaallit Nunaat)+299
  • Grenada+1
  • Guadeloupe+590
  • Guam+1
  • Guatemala+502
  • Guernsey+44
  • Guinea (Guinée)+224
  • Guinea-Bissau (Guiné Bissau)+245
  • Guyana+592
  • Haiti+509
  • Honduras+504
  • Hong Kong (香港)+852
  • Hungary (Magyarország)+36
  • Iceland (Ísland)+354
  • India (भारत)+91
  • Indonesia+62
  • Ireland+353
  • Isle of Man+44
  • Israel (‫ישראל‬‎)+972
  • Italy (Italia)+39
  • Jamaica+1
  • Japan (日本)+81
  • Jersey+44
  • Jordan (‫الأردن‬‎)+962
  • Kazakhstan (Казахстан)+7
  • Kenya+254
  • Kiribati+686
  • Kosovo+383
  • Kuwait (‫الكويت‬‎)+965
  • Kyrgyzstan (Кыргызстан)+996
  • Laos (ລາວ)+856
  • Latvia (Latvija)+371
  • Lebanon (‫لبنان‬‎)+961
  • Lesotho+266
  • Liberia+231
  • Libya (‫ليبيا‬‎)+218
  • Liechtenstein+423
  • Lithuania (Lietuva)+370
  • Luxembourg+352
  • Macau (澳門)+853
  • Macedonia (FYROM) (Македонија)+389
  • Madagascar (Madagasikara)+261
  • Malawi+265
  • Malaysia+60
  • Maldives+960
  • Mali+223
  • Malta+356
  • Marshall Islands+692
  • Martinique+596
  • Mauritania (‫موريتانيا‬‎)+222
  • Mauritius (Moris)+230
  • Mayotte+262
  • Mexico (México)+52
  • Micronesia+691
  • Moldova (Republica Moldova)+373
  • Monaco+377
  • Mongolia (Монгол)+976
  • Montenegro (Crna Gora)+382
  • Montserrat+1
  • Morocco (‫المغرب‬‎)+212
  • Mozambique (Moçambique)+258
  • Myanmar (Burma) (မြန်မာ)+95
  • Namibia (Namibië)+264
  • Nauru+674
  • Netherlands (Nederland)+31
  • New Caledonia (Nouvelle-Calédonie)+687
  • New Zealand+64
  • Nicaragua+505
  • Niger (Nijar)+227
  • Nigeria+234
  • Niue+683
  • Norfolk Island+672
  • Northern Mariana Islands+1
  • Norway (Norge)+47
  • Oman (‫عُمان‬‎)+968
  • Palau+680
  • Palestine (‫فلسطين‬‎)+970
  • Panama (Panamá)+507
  • Papua New Guinea+675
  • Paraguay+595
  • Peru (Perú)+51
  • Philippines+63
  • Poland (Polska)+48
  • Portugal+351
  • Puerto Rico+1
  • Qatar (‫قطر‬‎)+974
  • Réunion (La Réunion)+262
  • Romania (România)+40
  • Russia (Россия)+7
  • Rwanda+250
  • Saint Barthélemy+590
  • Saint Helena+290
  • Saint Kitts and Nevis+1
  • Saint Lucia+1
  • Saint Martin (Saint-Martin (partie française))+590
  • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
  • Saint Vincent and the Grenadines+1
  • Samoa+685
  • San Marino+378
  • São Tomé and Príncipe (São Tomé e Príncipe)+239
  • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
  • Senegal (Sénégal)+221
  • Serbia (Србија)+381
  • Seychelles+248
  • Sierra Leone+232
  • Singapore+65
  • Sint Maarten+1
  • Slovakia (Slovensko)+421
  • Slovenia (Slovenija)+386
  • Solomon Islands+677
  • Somalia (Soomaaliya)+252
  • South Africa+27
  • South Korea (대한민국)+82
  • South Sudan (‫جنوب السودان‬‎)+211
  • Spain (España)+34
  • Sri Lanka (ශ්‍රී ලංකාව)+94
  • Sudan (‫السودان‬‎)+249
  • Suriname+597
  • Svalbard and Jan Mayen+47
  • Swaziland+268
  • Sweden (Sverige)+46
  • Switzerland (Schweiz)+41
  • Syria (‫سوريا‬‎)+963
  • Taiwan (台灣)+886
  • Tajikistan+992
  • Tanzania+255
  • Thailand (ไทย)+66
  • Timor-Leste+670
  • Togo+228
  • Tokelau+690
  • Tonga+676
  • Trinidad and Tobago+1
  • Tunisia (‫تونس‬‎)+216
  • Turkey (Türkiye)+90
  • Turkmenistan+993
  • Turks and Caicos Islands+1
  • Tuvalu+688
  • U.S. Virgin Islands+1
  • Uganda+256
  • Ukraine (Україна)+380
  • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
  • United Kingdom+44
  • United States+1
  • Uruguay+598
  • Uzbekistan (Oʻzbekiston)+998
  • Vanuatu+678
  • Vatican City (Città del Vaticano)+39
  • Venezuela+58
  • Vietnam (Việt Nam)+84
  • Wallis and Futuna (Wallis-et-Futuna)+681
  • Western Sahara (‫الصحراء الغربية‬‎)+212
  • Yemen (‫اليمن‬‎)+967
  • Zambia+260
  • Zimbabwe+263
  • Åland Islands+358

I have read the Terms & Conditions and Privacy Policy. I agree to its terms.

Report Buying Options